Literature DB >> 28495150

Personalized Prognosis of Uveal Melanoma Based on Cytogenetic Profile in 1059 Patients over an 8-Year Period: The 2017 Harry S. Gradle Lecture.

Carol L Shields1, Emil Anthony T Say2, Murat Hasanreisoglu2, Jarin Saktanasate2, Brendan M Lawson2, Jeffrey E Landy2, Anjali U Badami2, Meera D Sivalingam2, Alexander J Hauschild2, Robert J House2, Zachary E Daitch2, Arman Mashayekhi2, Jerry A Shields2, Arupa Ganguly3.   

Abstract

PURPOSE: To determine the personalized rate of uveal melanoma-related metastasis on the basis of individual tumor cytogenetic profile.
DESIGN: Retrospective case series. PARTICIPANTS: A total of 1059 patients with uveal melanoma.
METHODS: Fine-needle aspiration biopsy (FNAB) for DNA amplification and whole genome array-based assay were performed for analysis of chromosomes 3, 6, and 8. MAIN OUTCOME MEASURES: Melanoma-related metastasis.
RESULTS: The mean patient age was 57 years, and most were white (1026/1059, 97%). The melanoma involved the choroid (938/1059, 89%), ciliary body (85/1059, 8%), or iris (36/1059, 3%), with 19% being macular in location. The mean largest basal diameter was 11 mm (median, 12 mm; range, 3-24 mm), and mean thickness was 5 mm (median, 4 mm; range, 1-20 mm). On the basis of individual chromosomal mutations, risk for metastasis was increased for chromosome 3 partial monosomy (hazard ratio [HR], 2.84; P = 0.001), 3 complete monosomy (HR, 6.7, P < 0.001), 6q loss (HR, 3.1, P = 0.003), 8p loss (HR, 21.5, P < 0.001), and 8q gain (HR, 9.8, P < 0.001). Kaplan-Meier estimate for melanoma-related metastasis in 1, 3, 5, and 7 years for 3 partial monosomy was 1%, 5%, 14%, and 17%; for 3 complete monosomy was 3%, 19%, 28%, and 37%; for 6q loss was 8%, 23%, 49%, and 49%; for 8p loss was 8%, 29%, not estimable (NE), and NE; and for 8q gain was 6%, 21%, 35%, 48%, respectively. On the basis of personalized cytogenetic profiles, Kaplan-Meier estimates (1, 3, and 5 years) for melanoma-related metastasis for 3, 6, and 8 disomy (1%, 1%, 4% [HR, 1]) were low compared with the higher-risk combinations of 3 complete monosomy, 6p gain, and 8q gain (0%, 29%, 29% [HR, 10.6, P = 0.02]); 3 complete monosomy, 6 disomy, 8q gain, and 8p gain (14%, 14%, NE [HR, 18.3, P = 0.02]); 3 complete monosomy, 6 disomy, and 8q gain (8%, 27%, 39% [HR, 19.5, P < 0.001]); and 3 complete monosomy, 6 disomy, 8q gain, and 8p loss (3%, 28%, NE [HR, 31.6, P < 0.001]), respectively.
CONCLUSIONS: Risk for melanoma-related metastasis strongly correlates with personalized cytogenetic profiles, with 5-year Kaplan-Meier estimates ranging from 4% with chromosomes 3, 6, and 8 disomy up to 39% for 3 complete monosomy, 6 disomy, and 8q gain.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28495150     DOI: 10.1016/j.ophtha.2017.04.003

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.

Authors:  Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya
Journal:  Retina       Date:  2018-11-08       Impact factor: 4.256

2.  Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy.

Authors:  Carol L Shields; Kareem Sioufi; Archana Srinivasan; Maura Di Nicola; Babak Masoomian; Laura E Barna; Vladislav P Bekerman; Emil A T Say; Arman Mashayekhi; Jacqueline Emrich; Lydia Komarnicky; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

3.  IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma.

Authors:  Eric Londin; Rogan Magee; Carol L Shields; Sara E Lally; Takami Sato; Isidore Rigoutsos
Journal:  Pigment Cell Melanoma Res       Date:  2019-08-16       Impact factor: 4.693

4.  Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.

Authors:  Fei Xia; Zhilong Yu; Aijun Deng; Guohong Gao
Journal:  Exp Biol Med (Maywood)       Date:  2021-11-07

5.  Accuracy of The Cancer Genome Atlas Classification vs American Joint Committee on Cancer Classification for Prediction of Metastasis in Patients With Uveal Melanoma.

Authors:  Mehdi Mazloumi; Pornpattana Vichitvejpaisal; Lauren A Dalvin; Antonio Yaghy; Kathryn G Ewens; Arupa Ganguly; Carol L Shields
Journal:  JAMA Ophthalmol       Date:  2020-03-01       Impact factor: 7.389

6.  Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.

Authors:  Prisca Bustamante; Thupten Tsering; Jacqueline Coblentz; Christina Mastromonaco; Mohamed Abdouh; Cristina Fonseca; Rita P Proença; Nadya Blanchard; Claude Laure Dugé; Rafaella Atherino Schmidt Andujar; Emma Youhnovska; Miguel N Burnier; Sonia A Callejo; Julia V Burnier
Journal:  J Exp Clin Cancer Res       Date:  2021-06-16

7.  CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.

Authors:  Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya
Journal:  Retina       Date:  2020-02       Impact factor: 3.975

Review 8.  Uveal Melanoma in Asians: A Review.

Authors:  Pradeep Manchegowda; Arun D Singh; Carol Shields; Swathi Kaliki; Parag Shah; Lingam Gopal; Pukhraj Rishi
Journal:  Ocul Oncol Pathol       Date:  2021-02-09

9.  Germline mutation in the TP53 gene in uveal melanoma.

Authors:  Nikola Hajkova; Jan Hojny; Kristyna Nemejcova; Pavel Dundr; Jan Ulrych; Katerina Jirsova; Johana Glezgova; Ivana Ticha
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

10.  Cytogenetic results of choroidal nevus growth into melanoma in 55 consecutive cases.

Authors:  Carol L Shields; Maria Pefkianaki; Arman Mashayekhi; Jerry A Shields; Arupa Ganguly
Journal:  Saudi J Ophthalmol       Date:  2018-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.